Literature DB >> 23843405

Cerebral venous thrombosis due to cryptogenic organising pneumopathy with antiphospholipid syndrome worsened by heparin-induced thrombocytopenia.

J Hsieh1, I Kuzmanovic, M I Vargas, I Momjian-Mayor.   

Abstract

Cerebral venous thrombosis (CVT) has usually been ascribed to prothrombotic conditions, oral contraceptives, pregnancy, malignancy, infection, head injury or mechanical precipitants. The case reported here illustrates two rare causes of CVT observed in the same patient: the presence of antiphospholipid antibodies associated with an asymptomatic cryptogenic organising pneumopathy (COP) which were considered the origin of the venous cerebral thrombosis and heparin-induced thrombocytopenia (HIT) which was responsible for the worsening of the thrombosis observed a few days after the introduction of treatment. Moreover, we provide here additional positive experience in the treatment of both, CVT and HIT, by fondaparinux with bridging to warfarin given their successful evolution under this anticoagulant option.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23843405      PMCID: PMC3736154          DOI: 10.1136/bcr-2013-009500

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis.

Authors:  Gabriela Cesarman-Maus; Carlos Cantú-Brito; Fernando Barinagarrementeria; Rosario Villa; Elba Reyes; Jorge Sanchez-Guerrero; Katherine A Hajjar; Ethel Garcia Latorre
Journal:  Stroke       Date:  2010-12-30       Impact factor: 7.914

2.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.

Authors:  N M Shah; M A Khamashta; T Atsumi; G R Hughes
Journal:  Lupus       Date:  1998       Impact factor: 2.911

Review 3.  Cerebral venous thrombosis and anticardiolipin antibodies.

Authors:  J R Carhuapoma; P Mitsias; S R Levine
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

4.  Cerebral venous thrombosis due to essential thrombocythemia and worsened by heparin-induced thrombocytopenia and thrombosis.

Authors:  Sebastien Richard; Julien Perrin; Karine Lavandier; Jean-Christophe Lacour; Xavier Ducrocq
Journal:  Platelets       Date:  2010-12-08       Impact factor: 3.862

5.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study.

Authors:  S Pérez Gutthann; L A García Rodríguez; J Castellsague; A Duque Oliart
Journal:  BMJ       Date:  1997-03-15

Review 6.  Central nervous system involvement in the antiphospholipid (Hughes) syndrome.

Authors:  G Sanna; M L Bertolaccini; M J Cuadrado; M A Khamashta; G R V Hughes
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

7.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

8.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.

Authors:  Theodore E Warkentin
Journal:  Thromb Haemost       Date:  2008-01       Impact factor: 5.249

10.  Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.

Authors:  Norbert Lubenow; Petra Eichler; Theresia Lietz; Beate Farner; Andreas Greinacher
Journal:  Blood       Date:  2004-07-27       Impact factor: 22.113

  10 in total
  4 in total

1.  Successful endovascular therapy for cerebral venous sinus thrombosis accompanied by heparin-induced thrombocytopenia.

Authors:  Yoshihisa Fukushima; Kenji Takahashi; Ichiro Nakahara
Journal:  Interv Neuroradiol       Date:  2020-03-01       Impact factor: 1.610

2.  Oral contraceptive-related transverse sinus thrombosis as an initial manifestation of antiphospholipid syndrome in the absence of systemic lupus erythematosus.

Authors:  Payam Saadat; Reza Mohseni-Ahangar
Journal:  Caspian J Intern Med       Date:  2017

3.  Cyclosporine-A-Induced Intracranial Thrombotic Complications: Systematic Review and Cases Report.

Authors:  Si-Ying Song; Zhong-Ao Wang; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  Front Neurol       Date:  2021-02-11       Impact factor: 4.003

4.  Cerebral Vein Thrombosis in the Antiphospholipid Syndrome: Analysis of a Series of 27 Patients and Review of the Literature.

Authors:  Alba Jerez-Lienas; Alexis Mathian; Jenifer Aboab; Isabelle Crassard; Miguel Hie; Fleur Cohen-Aubart; Julien Haroche; Denis Wahl; Ricard Cervera; Zahir Amoura
Journal:  Brain Sci       Date:  2021-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.